Astrazeneca's (AZN) "Sell" Rating Reiterated at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reiterated a "Sell" rating on AstraZeneca, though the analyst consensus remains a Moderate Buy (11 Buys, 1 Sell) with an average target price of $102.67.
• AstraZeneca beat Q1 EPS ($2.58) and revenue ($15.29B) expectations and reaffirmed 2026 guidance, reinforcing its growth narrative driven by oncology and rare‑disease sales.
• An FDA Oncologic Drugs Advisory Committee voted 6–3 against recommending camizestrant for first‑line HR+ advanced breast cancer, a negative development that has driven recent share weakness and raises regulatory risk.

Astrazeneca (NYSE:AZN - Get Free Report)'s stock had its "sell" rating restated by equities researchers at Deutsche Bank Aktiengesellschaft in a report released on Thursday,MarketScreener reports.

Other equities analysts also recently issued reports about the company. Citigroup initiated coverage on Astrazeneca in a research report on Tuesday, January 27th. They issued a "buy" rating for the company. TD Cowen reissued a "buy" rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Weiss Ratings began coverage on Astrazeneca in a research note on Wednesday, March 11th. They issued a "buy (b)" rating for the company. JPMorgan Chase & Co. reissued a "buy" rating on shares of Astrazeneca in a research note on Thursday, April 23rd. Finally, Morgan Stanley reissued an "overweight" rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $102.67.

Astrazeneca Stock Performance

NYSE:AZN traded down $1.58 during trading hours on Thursday, hitting $185.79. The company's stock had a trading volume of 126,608 shares, compared to its average volume of 2,756,855. Astrazeneca has a twelve month low of $132.32 and a twelve month high of $212.71. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $288.14 billion, a PE ratio of 31.35, a price-to-earnings-growth ratio of 1.40 and a beta of 0.35.

Astrazeneca (NYSE:AZN - Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.51 by $0.07. Astrazeneca had a return on equity of 31.01% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to analysts' expectations of $14.98 billion. On average, analysts anticipate that Astrazeneca will post 10.26 EPS for the current fiscal year.

Institutional Trading of Astrazeneca

A number of large investors have recently bought and sold shares of the company. Avid Wealth Partners LLC purchased a new stake in Astrazeneca in the first quarter worth $206,000. Mascoma Wealth Management LLC purchased a new position in shares of Astrazeneca in the first quarter valued at $26,000. ARGA Investment Management LP purchased a new position in shares of Astrazeneca in the first quarter valued at $2,264,000. Whipplewood Advisors LLC grew its position in shares of Astrazeneca by 1,093.8% in the first quarter. Whipplewood Advisors LLC now owns 955 shares of the company's stock valued at $188,000 after purchasing an additional 875 shares in the last quarter. Finally, Channing Global Advisors LLC grew its position in shares of Astrazeneca by 1,469.2% in the first quarter. Channing Global Advisors LLC now owns 167,622 shares of the company's stock valued at $32,489,000 after purchasing an additional 156,940 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: FDA panel backed AstraZeneca’s prostate cancer regimen, giving regulatory momentum to part of its oncology franchise — a near‑term positive for future approvals and revenues. Read More.
• Positive Sentiment: Strong Q1 results: AZN beat EPS and revenue expectations and reaffirmed 2026 guidance, supporting the company’s growth narrative driven by oncology and rare‑disease sales. Read More.
• Positive Sentiment: Citi raised its 2026 core EPS forecast and kept a Buy rating, highlighting attractive risk/reward ahead of multiple second‑half pipeline readouts. Analyst support can help underpin the stock. Read More.
• Positive Sentiment: DZ Bank upgraded AZN from Neutral to Buy, adding institutional endorsement to the bullish view after the earnings beat. Read More.
• Positive Sentiment: AstraZeneca exercised its option to license Pinetree’s EGFR degrader program (PTX‑299), triggering a $25M payment and expanding its targeted‑degrader pipeline — a financing and pipeline positive. Read More.
• Neutral Sentiment: Erste Group slightly trimmed its FY2026 EPS estimate for AZN (from $10.44 to $10.30), a modest forecast tweak that reflects caution but is close to consensus. Read More.
• Negative Sentiment: The key negative: an FDA Oncologic Drugs Advisory Committee voted 6–3 against recommending camizestrant for first‑line treatment in HR+ advanced breast cancer, citing trial‑design and benefit‑risk concerns — the vote has driven today’s share weakness and raises regulatory risk and potential delays for that indication. AstraZeneca says it will continue working with regulators. Read More.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.